MONTREAL, April 19,
2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH)
(OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"),
a Canadian pharmaceutical company, is pleased to announce that the
12% Convertible Unsecured Subordinated Debentures (the
"Debentures") issued pursuant to the $15.0 million bought deal private placement
closed on December 9, 2021, have been
approved for listing on the TSX under the symbol "VPH.DB" and will
begin trading on Tuesday April 19,
2022.
The Debentures have a maturity date of December 31, 2024 (the "Maturity Date"),
and accrue interest at the rate of 12% per annum payable
quartertly. At the holders' option, the Debentures may be
converted into Class A shares of the Company at any time and from
time to time, up to the Maturity Date, at a conversion price of
$1.15 per Class A share.
For additional details regarding the Debentures, please refer to
the Debenture Indenture dated December
9, 2021, which is available at www.SEDAR.com.
About Valeo Pharma
Valeo Pharma is a pharmaceutical company dedicated to the
commercialization of innovative prescription products in
Canada with a focus on
Respirology, Neurodegenerative Diseases, Oncology and other
specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full
capability and complete infrastructure to register and properly
manage its growing product portfolio through all stages of
commercialization. For more information, please visit
www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo Pharmas's objectives, strategies and businesses that involve
risks and uncertainties, including statements about the Offering,
the Concurrent Private Placement and the anticipated use of
proceeds therefrom. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.